Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch + Lomb Corporation filings document the reporting obligations of a Canada-incorporated eye health company whose common shares trade on the New York Stock Exchange and Toronto Stock Exchange under BLCO. Its 8-K reports cover quarterly and annual operating results, non-GAAP financial measures, guidance, investor presentations, material credit-agreement amendments and refinancing activity.
Proxy materials describe annual shareholder meeting matters, board composition, director independence, committee assignments and executive compensation governance. Other event filings record board appointments, committee changes, registered common-share details and Regulation FD disclosures tied to the company's product pipeline, Pharmaceuticals, Surgical and Vision Care operations.
Bausch + Lomb Corporation reported first-quarter 2026 results showing higher sales but a continued net loss. Revenues reached $1,244 million, up from $1,137 million a year earlier, driven by product sales across its Vision Care, Pharmaceuticals and Surgical eye-health segments.
Operating income improved to $33 million from an operating loss of $83 million, and the net loss attributable to the company narrowed to $71 million from $212 million, or $0.20 per share versus $0.60. Cash from operating activities was $32 million compared with a $25 million use of cash in the prior-year quarter. As of March 31, 2026, total assets were $13,780 million, long-term debt and other financial liabilities (net of issuance costs) were about $5,039 million, and cash and cash equivalents were $268 million. Bausch Health Companies Inc. continued to own roughly 87% of Bausch + Lomb’s common shares, with 356,536,358 common shares outstanding as of April 22, 2026.
Bausch + Lomb reported solid first-quarter 2026 growth and raised its full-year outlook. Revenue reached $1.244 billion, up 9% from the first quarter of 2025, or 6% on a constant currency basis, driven by all three segments.
Vision Care revenue grew to $711 million, Surgical to $228 million, and Pharmaceuticals to $305 million, with Pharmaceuticals up 14% and led by strong MIEBO and XIIDRA sales. Operating results improved markedly, shifting from an operating loss of $83 million to operating income of $33 million.
The company still posted a GAAP net loss of $71 million, but adjusted net income was $19 million and cash flow from operations turned positive at $32 million. Adjusted EBITDA rose to $189 million, or $200 million excluding acquired IPR&D, prompting higher 2026 revenue and adjusted EBITDA guidance.
Bausch & Lomb Corp President, GPIC Andrew J. Stewart reported a routine tax-withholding share disposition. On the vesting of restricted share units, 4,216 common shares were withheld at $15.82 per share to cover tax obligations. After this non-market transaction, he holds 86,433 common shares directly.
Bausch & Lomb Corp executive Robert D. Bailey, EVP & Chief Legal Officer, reported a routine tax-related share disposition. On this Form 4, 15,806 common shares were withheld at $15.82 per share to cover tax withholding obligations from vesting restricted share units. Following this withholding, Bailey directly holds 230,684 common shares, indicating this was not an open-market sale but a standard mechanism to satisfy taxes due at vesting.
Bausch + Lomb Corporation is asking shareholders to vote at its virtual 2026 Annual Meeting on May 20, 2026. Investors will elect ten directors, hold an advisory vote on executive pay, and decide on amending the 2022 Omnibus Incentive Plan to add 25,000,000 common shares for equity awards.
Shareholders will also vote on appointing PricewaterhouseCoopers LLP as auditor and receive the 2025 audited financial statements. The proxy highlights a largely independent, skills‑based board, detailed committee structure, strong ESG oversight, and extensive sustainability initiatives, including a 2050 net zero goal and expanded recycling and decarbonization programs.
Bausch & Lomb Corp executive Robert D. Bailey, EVP & Chief Legal Officer, reported new activity in company stock. On March 6, 2026, he made an open-market purchase of 14,600 common shares at an average price of $17.146 per share, held in his self-directed IRAs.
In connection with this purchase, he also acquired 14,600 matching restricted share units (MRSUs) under the company’s matching share program. These MRSUs vest in three equal annual installments over three years, contingent on his continued service, bringing his direct holdings to 246,490 common shares after the reported transactions.
Bausch & Lomb Corp Executive Vice President and CFO Sam Eldessouky reported new insider activity in common shares. He made an open-market purchase of 4,000 common shares at $17.13 per share, increasing his direct ownership.
In connection with this purchase, he was also granted 4,000 matching restricted share units (MRSUs) under the company’s matching share program. One-third of these MRSUs will vest on each of the first, second, and third anniversaries of the grant date, subject to his continued service. Following these transactions, he directly holds 407,130 common shares.
Bausch & Lomb Corp CEO and Chairman Brent L. Saunders reported buying 14,700 common shares in an open-market transaction at a weighted average price of about $17.14 per share, with trade prices ranging from $17.09 to $17.19. He also received 14,700 matching restricted share units under the company’s matching share program, which vest in three equal annual installments if he continues in service. Following these transactions, he directly holds 981,275 common shares.
Bausch & Lomb Corp director Ross Thomas W. Sr. reported two transactions in common shares. He made an open-market purchase of 4,500 common shares at a weighted average price of $17.679 per share, increasing his direct holdings to 64,891 shares immediately after the trade. In connection with this purchase, he also acquired 4,500 matching restricted share units (MRSUs) under the company’s matching share program, bringing his total reported direct holdings to 69,391 shares. One-third of these MRSUs will vest on each of the first, second, and third anniversaries of the grant date, subject to his continued service, with limited exceptions.